News >

Expert Discusses Rapid Advances, Next Steps in Multiple Myeloma

Gina Columbus
Published: Thursday, Aug 03, 2017

Peter Voorhees, MD

Peter Voorhees, MD

Novel agents and treatment combinations have rapidly expanded the armamentarium in multiple myeloma. However, additional progress is needed to extend these successes to a greater population of patients, according to Peter Voorhees, MD.

on Hematologic Malignancies.

OncLive: What treatments are available for newly diagnosed patients with multiple myeloma?

Voorhees: I had the opportunity to talk about the treatment of newly diagnosed patients who are not necessarily eligible for autologous stem cell transplantation. There are 3 things in particular that are worth commenting on. First off, there has been a larger body of literature that has come forth supporting the paradigm of continuous treatment until disease progression. The FIRST trial is a good example of that. This was a randomized phase III study that has been published for a few years now, which compared continuous lenalidomide (Revlimid)/dexamethasone therapy versus 18 months of treatment. There was a clear improvement in PFS with [the continuous] approach. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication